Aktana Acquires Tact.ai’s Field Engagement and Conversational AI Technology
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the acquisition of Tact.ai’s field engagement and conversational AI technology. The addition extends Aktana’s leadership in field intelligence by delivering several new capabilities frequently requested by commercial and medical leaders overseeing omnichannel programs:
- Real-time delivery of suggestions and insights on the mobile phone
- Pervasive and on-demand recommendations throughout the user experience, including a conversational AI assistant
- Richer engagement data to improve AI recommendations
“Today’s sales rep or MSL is being asked to do more in less time and with fewer resources than ever before, and they need immediate access to the best intelligence on their most preferred device, the mobile phone,” said John Vitalie, CEO, Aktana. “Adding aspects of Tact.ai’s mobile technology and easy-to-use interface to the Aktana portfolio will accelerate our customers’ efforts to create the next-generation field force, one that’s powered by intelligence and adept at using any channel to support their HCPs.”
“Tact.ai set out to build human-friendly technology that connects life science companies and their customers, to help patients who can't wait,” said Chuck Ganapathi, CEO, Tact.ai. “Critical to that mission is a system of intelligence that fuels every interaction. As the pioneer of this category and with Tact.ai’s technology, Aktana is now even better positioned to lead this journey toward the future of customer engagement.”
Introducing Aktana Copilot
Powered by Tact.ai technology, Aktana today announced Aktana Copilot, an AI assistant on the mobile phone for life sciences field users. Specifically designed for the needs of field sales representatives and medical science liaisons, Aktana Copilot puts market and HCP intelligence in the hands of those users at the moment they need it.
Field teams will receive programmable and intelligence-driven nudges in real-time on mobile devices to simplify call planning with curated insights to drive more personalized and coordinated activity. In addition, recommendations will be presented through conversational AI throughout the user experience saving valuable time that can be repurposed for HCP relationship-building.
Through Aktana Copilot, customers can capture richer and more tailored engagement data which enables Aktana AI to produce more contextual and effective recommendations for users to have better conversations. The dynamic feedback loop improves time-to-value because as the speed in which recommendations improve accelerates, so too does campaign performance.
“Today’s announcements deepen our commitment to transforming customer engagement programs for life sciences organizations of all sizes,” said Derek Choy, founder and Chief Product Officer, Aktana. “The Strategy Suite that we unveiled at the Aktana Innovation Exchange last month will be enhanced with Aktana Copilot, providing a real-time connection between commercial leaders and the field. This can be used to get feedback from the field on tactics impacting their HCPs, and to nudge the field on tactics proven to have the highest impact.”
Aktana Copilot is available globally today and will be enhanced for specific use cases across commercial pharma, medical affairs and medical devices throughout 2024. Aktana will also offer Microsoft Teams users a version of Tact Presenter which is the only Microsoft Teams certified remote detailer for Veeva content.
Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana
Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc
About Aktana
Aktana is the leader in intelligent customer engagement for the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 350 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the world’s top 20 pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more, visit www.aktana.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101732293/en/
Contact information
Debby Fry Wilson
deborah.wilson@aktana.com
425-638-9617
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Announces the Jury for the First AI Music Contest: Finalists Will Perform Live on Stage at Kappa FuturFestival in Turin23.5.2025 11:05:00 EEST | Press release
Reply, an international group specialized in the creation of new business models enabled by Artificial Intelligence and driven by a strong culture of innovation, is expanding its creative experimentation initiatives this year with the launch of the AI Music Contest. Organised in collaboration with Kappa FuturFestival, one of Europe’s leading electronic music festivals, the competition is open to creatives and innovators who use AI technologies to explore new forms of integration between sound and visuals. It aims to enhance the expressive potential of artificial intelligence in live performances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250523250887/en/ The jury members include prominent figures such as Seth Troxler and DJ Tennis, who are renowned DJs and producers known for their pioneering use of AI in live performances. Also on the panel is Albertino, a DJ, radio host and the artistic director of Radio m2o. Alongsid
Kioxia Holdings Corporation Wins IPO of the Year Award in the Equity Category at the DealWatch Awards 202423.5.2025 10:00:00 EEST | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced that it had won the IPO of the Year award in the Equity category at the DealWatch Awards 2024, organized by DealWatch, the most authoritative source of real-time intelligence for deal activity within Japan's capital markets. The award was presented at a ceremony held on May 20. The DealWatch Awards recognize outstanding issuers of bonds or equities in the Japanese capital market, as well as Japanese issuers who have conducted offerings overseas, and the securities firms that manage these transactions. The awards for 2024 comprised six categories: Overall, Bonds, Local Government Bonds, Cross-Border Bonds, Sustainable Finance, and Equity. Selection is based on criteria such as the appropriateness of pricing in the issuance market, price formation after transition to the trading market, contribution to the development of capital markets, and innovative efforts, with the awards designed to promot
Generix Named in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS) for the Seventh Consecutive Year23.5.2025 10:00:00 EEST | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, today announces it has been recognized by Gartner in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS). This is the seventh consecutive year that Generix has been recognized for its portfolio of WMS Solutions. Designed to scale as supply chain operations grow from simple to complex flows, Generix WMS and Solochain WMS are currently in more than 2,000 warehouses globally. “We are honored to be recognized in the Gartner® Magic Quadrant™ WMS for the seventh consecutive year. Generix continues its commitment to providing WMS for every warehousing need at a global scale. With our two recognized WMS solutions, Generix WMS and Solochain WMS, we continue to innovate to better serve customer needs with the introduction of industry game-changing AI use-cases such as resource planning and computer vision,” said Si-Mohamed Sa
NuORDER by Lightspeed and Mandatory Renew Partnership to Power Hybrid Commerce at the Third Edition of the Copenhagen Event23.5.2025 10:00:00 EEST | Press release
Mandatory and NuORDER by Lightspeed, the industry’s leading B2B commerce platform, are joining forces for the third consecutive time to power the digital extension of Mandatory’s in-person trade event, taking place August 5–7 in Copenhagen. This renewed partnership reflects the continued momentum behind hybrid commerce—where physical and digital trade intersect to create smarter, more flexible buying experiences. As the Nordic fashion ecosystem expands with energy and innovation, Mandatory has become a magnet for trendsetting brands and forward-looking retailers. On NuORDER’s wholesale platform, buyer activity from Nordic-region retailers surged by 39.4% year over year in Q1 2025 (January to March). "Retailers in the Nordic region have been quick to adopt digital tools to enhance the efficiency of their buying processes. The increase in buyer activity on the NuORDER platform early this year clearly indicates a growing market demand and a renewed engagement within the industry," said Ch
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 08:00:00 EEST | Press release
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis intends to develop corticorelin to treat PTBE in primary and metasta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom